1.	Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ADO-MM-PAL8, NCT00226473
2.	HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12PLK01, NCT01683188
3.	Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Trial Photoderm Graz 2010-1, NCT01088737
4.	A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007
5.	Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: MM-ADJ-5, NCT00226408
6.	Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 05 DIVE 03, NCT00224744
7.	Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma Phase: Phase III Type: Treatment Status: Active Age: Under 75 Sponsor: Other Protocol IDs: BRD/04/1-D, NCT00200577
8.	Multicenter Selective Lymphadenectomy Trial II (MSLT-II) Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: MSLT-II, NIH P01 CA029605, NCT00297895
9.	Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 101.321-13/07, EudraCT Nr. 2008-001686-28, NCT00779714
10.	Study Comparing Isolated Pelvic Perfusion With TNF-a 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 76 Sponsor: Other Protocol IDs: PIP2, CSET 1443, NCT00949039
11.	Neurotropic Melanoma of the Head and Neck Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TROG 08.09, 2009/039, NCT00975520
12.	Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-154, NCT01223248
13.	MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: S480/209, 2009-012049-46, NCT01264874
14.	Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1609, E1609, NCT01274338
15.	A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AB08026, NCT01280565
16.	A Study of RO5185426 in Patients With Metastatic Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO25515, NCT01307397
17.	Melanoma Margins Excision Trial Phase: Phase III Type: Health services research, Supportive care, Treatment Status: Approved-not yet active Age: 18 to 85 Sponsor: Other Protocol IDs: 2011PLAS03, NCT01457157
18.	Adjuvant PEG Intron in Ulcerated Melanoma Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 to 70 Sponsor: Other Protocol IDs: EORTC-18081, 2009-010273-20, NCT01502696
19.	Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ANZMTG 1-07, ACTRN12607000512426, NCT01503827
20.	Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: 103A-301, NCT01546571
21.	A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115306, NCT01584648
22.	Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 116513, NCT01597908
23.	Melanoma Gamma Knife Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0875, NCT01644591
24.	A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GO27826, 2011-004011-24, NCT01667419
25.	A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115532, NCT01682083